title: Adenoviral interleukin-3 gene-radiation therapy for prostate cancer in mouse model.
abstract: OBJECTIVE
  The radiosensitizing effect of IL-3 gene therapy was evaluated on the syngeneic mouse prostate cancer model.
  
  
  METHODS
  An adenoviral vector was used to deliver the mIL-3 alpha gene into syngeneic murine prostate (TRAMP-C1) cancer cells growing in a subcutaneous site and the tumor response to irradiation was assessed.
  
  
  RESULTS
  Ad-mIL-3 gene therapy showed no tumor growth delay without radiation. However, intratumoral Ad-mIL-3 injection with radiation therapy showed marked tumor growth delay that was significantly greater than that of radiation alone.
  
  
  CONCLUSIONS
  The combined intratumoral Ad-mIL-3 gene therapy and radiation therapy is a valuable option for further clinical evaluation.
authors.affiliation: Department of Radiation Oncology, Ajou University School of Medicine, Paldal Gu, Suwon, South Korea. ohyoung@ajou.ac.kr
authors.forename: Young-Taek
authors.initials: YT
authors.lastname: Oh
authors.forename: Daniel W C
authors.initials: DW
authors.lastname: Chen
authors.forename: Graeme J
authors.initials: GJ
authors.lastname: Dougherty
authors.forename: William H
authors.initials: WH
authors.lastname: McBride
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D017209:Apoptosis; D003131:Combined Modality Therapy; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000627:therapeutic use; D007377:Interleukin-3 / Q000235:genetics* / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000532:radiotherapy / Q000628:therapy*; D011879:Radiotherapy Dosage
chemical_list: D007377:Interleukin-3